G2GBIO sells the technology to make 'long-acting injectables' that release a drug slowly inside the body over a month or more, developing a donepezil dementia injectable and GLP-1 obesity and diabetes injectable candidates on its microsphere (tiny drug-bead) platform 'InnoLAMP.' Revenue in 2025 came to only ₩400 million, so it is still effectively a development-stage company with almost no product sales and continuing operating losses; but in March 2026 it signed a large technology-transfer and co-development deal handing InnoLAMP technology to a Samsung Bioepis affiliate, and secured large-scale funding through convertible preferred shares and convertible bonds. What stands out lately is the pairing of a strength — if the partner succeeds in clinical trials and commercialization, upfront and milestone payments plus manufacturing could feed through to results with big potential — and a caution: most candidates are still in early clinical stages, so it will take time to confirm results, and losses and R&D spending continue until then.
At-a-glance assessment financial health · growth · profitability · valuation
- The most recent full-year net result was a loss.
- Revenue fell 45.0% year over year (3-year trend: mixed).
- Most recent quarter (Q1 2026) revenue was 4364.3% higher than a year earlier.
- ROE is -20.7% (total-net basis). It is below the sector average.
- Operating margin is -2884.2%.
- P/E is hard to compute here, so this is read on P/B.
Ownership & governance As of 2025-12-31
Largest shareholder Lee Hee-yong 11% (individual)
Controlling bloc incl. related parties 16.4%
With the controlling bloc holding 16%, control is maintained but the free float is relatively large.
🔎 In-depth analysis
- Rather than a company that sells its own new drugs, G2GBIO is a platform company that makes 'technology to make a drug last a long time,' hands it to other pharmaceutical firms and even takes on manufacturing.
- Its core technology is InnoLAMP, which uniformly loads a drug inside tiny drug beads (microspheres) made of biodegradable polymer and releases it slowly inside the body over a month or more.
- This can turn a drug taken daily or injected often into one shot a month, greatly improving patient convenience.
- Representative candidates include a one-month-lasting dementia injectable based on donepezil (GB-5001), a long-acting GLP-1 obesity and diabetes injectable based on semaglutide, and a post-surgical pain treatment.
- Revenue is almost nil for now, but the company's real assets are this platform technology and its mass-production facilities, and its money comes from technology-transfer upfronts, milestone payments, royalties and contract manufacturing.
- The shares sit at a level where early-listing hopes gathered and then corrected heavily.
- The current price of ₩31,600 is below both the 20-day line (about ₩40,565) and the 60-day line (about ₩58,582), so the medium-term trend is weak.
- It sits about 86% below the 52-week high, with most of the immediate post-listing surge retraced.
- The RSI is about 30, near oversold, so the short-term decline has progressed considerably.
- That said, this is a stock whose price moves largely on events such as technology transfers and clinical results rather than on earnings, so the pipeline and deal progress steer the direction more than the chart position.
- G2GBIO is a development-stage company that does not yet turn a profit.
- Revenue in 2025 was ₩400 million, with an operating loss of about ₩12.2 billion and a net loss of about ₩12.1 billion.
- ROE (how much is earned in a year on equity) is -20.7%, a loss position, and the P/E (how many times one year of profit the share price is) cannot be calculated because there is no profit.
- So this company does not fit well with profit- and book-based metrics such as P/E and P/B.
- Financial stability is actually rather sound.
- The current ratio is 735%, so near-term liquidity is ample, and subtracting cash from total borrowings leaves net cash (more cash than debt), so immediate financial risk is low.
- The 2024 net loss of ₩83.3 billion was unusually large, but that was mostly a non-cash financial loss arising from re-measuring, for accounting purposes, the convertible preferred shares and convertible bonds issued before listing; the actual operating loss was far smaller.
- After listing, these derivative-valuation-loss factors decline greatly.
- Looking at revenue alone, 2025 fell 45% from the prior year, a numerical decline.
- But this company's revenue is by nature lumpy, recognized when technology-transfer consideration is booked rather than from product sales, so growth cannot be judged from year-on-year revenue change.
- The actual flow changed greatly in 2026.
- Cumulative first-quarter 2026 revenue rose 4,364% from the same period a year earlier; the base is so small that the absolute amount is still tiny, but it is a sign that technology-transfer and collaboration deals have begun to be booked as revenue.
- Future growth comes from the milestone payments received as the InnoLAMP technology-transfer deal with the Samsung Bioepis affiliate progresses through clinical stages, and from contract-manufacturing revenue upon later commercialization.
- Losses are likely to continue this year too on R&D spending, so confirmation of growth hinges on clinical progress and whether further partnerships come through.
- The first half of 2026 was the period with the most significant events in the company's history.
- On March 16 it disclosed a joint-research and technology-transfer deal handing the InnoLAMP platform to a Samsung Bioepis affiliate and co-developing it.
- It transferred exclusive rights to candidates including a one-month-lasting semaglutide, with the company taking on production and supply, securing upfront, milestone and royalty payments plus commercial-production revenue.
- Around the same time it issued convertible preferred shares and convertible bonds on a large scale to secure funds for clinical trials and facility expansion, with the Samsung side also participating via convertible bonds.
- Earlier, in September 2025 it signed a research-collaboration deal on developing sustained-efficacy injectables, and in October 2025 it carried out a bonus (free) share issuance.
- In April and July 2026 it held IRs to share business progress.
- G2GBIO is a company to be viewed by the value of its platform technology rather than by earnings.
- The strengths are clear.
- InnoLAMP is a long-acting injectable platform that is rare domestically, and the company actually landed a technology-transfer and co-development deal with a large domestic bio firm, validating its technical capability.
- Financially, net cash and ample liquidity mean little immediate funding pressure.
- On the other hand, the cautions are clear.
- Most candidates are still in early clinical stages, so it will take years to feed through to revenue, and in the meantime losses and cash burn continue on R&D spending.
- If the partner fails to produce results in the clinic or development is delayed, the expected milestone payments and royalties could be pushed back.
- In sum, this is a stock that strengthens when clinical progress and further technology transfers go smoothly, revaluing the platform, and weakens when clinical delays or cash burn come to the fore.
- That is why it should be watched around pipeline events rather than profit or dividends.
🔎 Valuation vs peers Inconclusive
Not a commercialized company judged by profit and product sales, but a development-stage platform bio whose value is recognized by transferring platform technology to other pharmaceutical firms. Similar-natured domestic platform bios (such as Alteogen) are currently valued on technology-transfer potential rather than profit and trade at very high multiples.
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Alteogen | 113.48x | 36.11x | 31.82% |
| ST Pharm | 45.22x | 4.19x | 9.27% |
G2GBIO does not turn a profit, so the P/E (how many times one year of profit the share price is) cannot be calculated, and the P/S is extremely high because product sales are almost nil. In other words, over- or undervaluation is hard to call by ordinary profit and revenue metrics. The P/B is about 9x, which looks high, but this book value precedes the full reflection of the large 2026 fundraising, so reading it as-is could mislead. Real value hinges on the InnoLAMP platform and the size, progress and clinical success probability of its technology-transfer deals. Given that similarly natured platform bios trade at high multiples on technology-transfer potential rather than profit, this company's fairness is hard to judge by profit metrics alone until pipeline results take shape. So 'Inconclusive' is appropriate for now.
Price history Close · MA20 · MA60
The latest close is ₩31,600 and the market capitalization is ₩525.5 billion. The price sits below its 20-day moving average (₩40,565) and below its 60-day moving average (₩58,582). It is under both its short- and medium-term moving averages, so the trend looks subdued. The RSI (a supplementary indicator that gauges the strength of gains versus losses over the past 14 days on a 0-100 scale) is 29.9, near oversold territory. The one-month change is -32.3%, the three-month change is -52.3%, and the position relative to the 52-week high is -86.6%. Relative strength versus the KOSDAQ is 3 (on a 1-99 scale, converted from returns against the index over the past year with more weight on recent performance; higher means stronger than the market). It is stronger than roughly 2% of all stocks. Over the past three months it lagged the index by 36.2%. Chart interpretation is best done alongside trading volume and the dates on which disclosures occur.
Relative performance stock vs index · start = 100
Excess return vs index · 3M -36.21% / 6M -39.80% / 12M -65.41%
Key metrics vs sector median
Valuation
A net loss makes the P/E an unreliable valuation gauge. The P/B of 9.01x is above the sector median (1.37x).
Enterprise value (EV)
EV = market cap + net debt. It reflects cash and debt, so it captures the real cost of the whole business that market cap alone misses; lower multiples are cheaper relative to earnings or sales.
Profitability & financials
Return on equity (ROE) is -20.7%, below the sector average (3.0%). The operating margin is -2884.2%. The debt ratio is 116.1%, so the financial structure is moderate.
Growth FY2025 · annual report (separate)
| Item | 2023 | 2024 | 2025 | YoY |
|---|---|---|---|---|
| Revenue | $490,335 | $509,627 | $280,400 | -44.98% ↓ slower |
| Operating profit | -$8.7M | -$7.1M | -$8.1M | — |
| Net profit | -$7.0M | -$55.2M | -$8.0M | — |
| 5-year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | $490,335 | $509,627 | $280,400 |
| Operating profit | — | — | -$8.7M | -$7.1M | -$8.1M |
| Net profit | — | — | -$7.0M | -$55.2M | -$8.0M |
| Revenue CAGR | 2-yr avg -24.38% | ||||
Revenue fell 45.0% year over year (2023 ₩739,823,074 → 2024 ₩768,930,985 → 2025 ₩423,070,926), and the three-year trend is 'mixed'. The rate of decline widened from the prior year. Operating results are in the red, so a swing back to profit matters more than the growth rate here. Over the 3 years on record, revenue compound annual growth (CAGR) is -24.4%. The two-year revenue CAGR is -24.4%. In the most recent quarter (Q1 2026), revenue was 4364.3% higher than the same period a year earlier.
Latest quarterly results Q1 2026 · vs year-ago
Technical indicators
What stands out
- —
Points to watch
- The most recent full year was a loss, so it is worth checking whether profitability recovers.
- Revenue fell 45.0% year over year (3-year trend: mixed).
- The price is high versus peers, so expectations already appear priced in.
Recent news & events searched · sourced
- 2026-03-16FilingSigned a joint-research and technology-transfer deal with a Samsung Bioepis affiliate for the InnoLAMP (long-acting microsphere drug-delivery) platform. Exclusive transfer of candidates such as a one-month-lasting semaglutide, with the company handling production and supply.The company's largest-ever technology transfer, which over the medium term could feed through to upfront, milestone, royalty and contract-manufacturing revenue. A key basis for validating the platform's value. Source
- 2026-03-16FilingDecision to issue convertible bonds. Large-scale funding to secure money for clinical trials and facility expansion, with the Samsung side also participating via convertible bonds.Short term, it bolsters funds for development and expansion. Potential share-count increase (dilution) upon conversion is a factor, but the wider funding room supports clinical continuity. Source
- 2026-03-12FilingDisclosure of the results of the third-party-allotment convertible preferred shares and convertible bonds (5th round). The large-scale fundraising is in its final stage.Secures funds to prepare for clinical trials and commercialization, strengthening development continuity. Future conversion volume is a share-count increase factor. Source
- 2025-09-29FilingSigned a research-collaboration deal on developing sustained-efficacy injectables.An early sign, over the medium term, of expanding the collaboration pipeline using the platform. Source
- 2025-10-22FilingDecision on a bonus (free) share issuance.Adjusts trading conditions by increasing the number of tradable shares. It does not change the corporate value itself. Source
- 2026-07-01IRIR held. Explanation of business and pipeline progress.Short term, it provides a basis for investment judgment by sharing information on clinical and deal progress. Source
Figure cross-check computed ↔ external
| Metric | Computed | External | Status | Source |
|---|---|---|---|---|
| 2025 revenue / net loss | revenue 4.2, approx. 121 | (2025.12) (2026-03-18) | Confirmed | link |
| First-quarter 2026 results | revenue 3.5, 33, 55 | (2026.03) (2026-05-15) | Confirmed | link |
| Samsung-affiliate technology-transfer deal | 2026-03-16 · approx. | (2026-03-16) | Confirmed | link |
| 2026 net profit estimate | — | — | Unverified | link |
Recent filings
- 2026-06-05OwnershipOfficers'/major-shareholders' holdings report
- 2026-06-05OwnershipOwnership-change filing
- 2026-06-05OwnershipAmended filing
- 2026-06-05OwnershipAmended filing
- 2026-06-05OwnershipAmended filing
- 2026-05-22OwnershipOfficers'/major-shareholders' holdings report (amended)
- 2026-05-21OwnershipOfficers'/major-shareholders' holdings report
- 2026-05-21OwnershipOfficers'/major-shareholders' holdings report
- 2026-05-21OwnershipOfficers'/major-shareholders' holdings report
- 2026-05-15PeriodicQuarterly report
- 2026-04-14Disclosure
- 2026-04-14Disclosure
📖 Plain-language glossary — expand if you are new to this
- P/E
- How many times a year's net profit the price is worth (lower is cheaper relative to earnings). The P/E here is on trailing (last full-year) results; for companies whose earnings swing fast (memory chips and other cyclicals/high-growth), a forward P/E on this year's expected earnings is more accurate.
- P/B
- Price relative to net assets (equity). Around 1x means it trades near book value; below 1x means below book.
- P/S
- Price relative to a year's revenue — useful for growth companies with thin earnings.
- Net debt / EV
- Net debt = interest-bearing debt − cash. Negative means more cash than debt (net cash). EV (enterprise value) = market cap + net debt, closer to what it would cost to buy the whole business.
- EV/EBIT · EV/EBITDA · EV/Sales
- Enterprise value against operating profit (EBIT), EBITDA, or revenue. Unlike P/E these reflect debt and cash; lower is cheaper relative to earnings power or sales.
- FCF / FCF yield
- Free cash flow = operating cash − capex, the cash actually left over. FCF yield = FCF ÷ market cap; higher means more cash generated per unit of market value.
- Intrinsic value (DCF)
- Future free cash flow (or, for some capex-heavy but profitable names, forecast earnings) discounted to today to estimate per-share value. Because it shifts a lot with the discount-rate and growth assumptions, it is shown as a bear/base/bull range, and the basis and assumptions are disclosed in one line beneath it.
- ROE
- How much profit the company earns in a year on its equity (%). Higher means better returns on capital.
- EPS / BPS
- Earnings per share / net assets (book value) per share.
- Operating / net margin
- Profit left from the core business / final profit after tax and interest, per unit of revenue.
- Debt ratio
- Debt relative to equity (%). Higher means more reliance on borrowing (norms vary by sector).
- Current ratio
- Assets convertible to cash within a year against debt due within a year. Above 100% leaves some short-term headroom.
- Interest coverage
- How many times operating profit covers the interest owed. Below 1x means operating profit alone struggles to cover interest.
- Dividend yield / payout ratio
- The year's dividend as a % of today's price / the share of earnings paid out as dividends.
- Revenue CAGR
- Multi-year growth expressed as a single yearly average (compound annual growth rate).
- RSI (short-term signal)
- Whether recent price action is overheated or beaten down. Above 70 is overbought, below 30 oversold.
- MA20 / MA60 (moving averages)
- The 20- and 60-day average price. Price above them signals a firmer short-term trend.
- vs 52-week high
- How far below the past year's peak the price sits now (%).
All figures are for reference only; how they read varies by sector and over time.
Sources: Korea FSC market-price API (data.go.kr), OpenDART, KRX/KIND — public data only.
Bong Stocks presents public-data-based information for reference only. It is not investment advice and contains no target prices, ratings, or buy/sell recommendations. Verify independently before making any decision.